Theriva Biologics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Theriva Biologics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 5,799% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 95% of Healthcare companies in United States.
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 94% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.2 times its market value (net cash). Higher than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-221.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 89% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-292.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 94% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× cashCash, after subtracting all debt, is 1.2 times its market value (net cash).
Higher than 90% of Healthcare companies in United States.
Tangible Assets Ratio
49%Of every $100 the company owns, $49 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 82% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 81% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Theriva Biologics, Inc. owes $0.65 for every $1 it owns. Theriva Biologics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
0.3Investors pay $0.3 for every $1 of Theriva Biologics, Inc.'s yearly profit, lower than 95% of Healthcare companies in United States.
P/B ratio
0.72The share price is 0.72 times Theriva Biologics, Inc.'s book value per share, lower than 86% of Healthcare companies in United States.
Market cap
$9 MThe total market value of all of Theriva Biologics, Inc.'s shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$12 MWhat Theriva Biologics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.27Net worth divided by the number of shares. The share price of $0.19 is 0.7 times this, which is the P/B above.
Return on equity (ROE)
-101.9%Theriva Biologics, Inc. lost 101.9% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
Owes vs Owns
0.65×Theriva Biologics, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Dividend yield
NoneTheriva Biologics, Inc. does not currently pay a dividend.
Profit growth
LossTheriva Biologics, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashTheriva Biologics, Inc. held $10 M more cash than debt (net cash) at Dec 2025.
Questions
What is Theriva Biologics, Inc.'s P/E ratio?
Investors pay $0.3 for every $1 of Theriva Biologics, Inc.'s yearly profit, lower than 95% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Theriva Biologics, Inc.: $9 M ÷ $12 M (30 Jun 2026) = 0.7.
What is Theriva Biologics, Inc.'s return on equity?
Theriva Biologics, Inc. lost 101.9% of its shareholders' money over the last year, lower than 71% of Healthcare companies in United States.
How much does Theriva Biologics, Inc. owe compared with what it owns?
Theriva Biologics, Inc. owes $0.65 for every $1 it owns (moderate), higher than 68% of Healthcare companies in United States.
Does Theriva Biologics, Inc. pay a dividend?
No. Theriva Biologics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.